Who is sponsoring NCT01888354?

NCT01888354 is sponsored by The University of Texas Health Science Center, Houston.

What condition does NCT01888354 study?

NCT01888354 studies Multiple Sclerosis (MS).

What drugs are being tested in NCT01888354?

Interventions: H.P. Acthar Gel (repository corticotropin injection).

What is the status of NCT01888354?

NCT01888354 is currently COMPLETED.

Last reviewed 2014-09-14 · How we verify

Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ) Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations

NCT01888354 Phase 4 COMPLETED

This pilot study is designed as a prospective cohort study to determine whether standard subcutaneous (SQ) Highly-Purified (HP) Acthar Gel 14 days is superior to SQ HP Acthar Gel 5 days in the treatment of relapses or attacks in multiple sclerosis (MS).

Details

Lead sponsor	The University of Texas Health Science Center, Houston
Phase	Phase 4
Status	COMPLETED
Enrolment	25
Start date	2013-04
Completion	2014-08

Conditions

Multiple Sclerosis (MS)

Interventions

H.P. Acthar Gel (repository corticotropin injection)

Primary outcomes

Comparison of EDSS Mean Recovery between 5-day vs 14-day SQ 80 IU ACTHar Gel therapy groups — 28 Days (with 90 day follow-up)
To determine whether a standard 14 day course of SQ 80 IU ACTHar Gel therapy might be superior (in twice as many patients) to treatment with 5 day SQ regimen for ACTHar Gel as determined by EDSS mean recovery from Day 0 (time of steroid therapy initiation) to Day 28 (and day 90).

Countries

United States